Back to results
US 6,642,241 B1Granted
Alkylamino-substituted bicyclic nitrogen heterocycles
AssigneeSyntex (U.S.A.) Inc.
InventorsJames Patrick Dunn, David Michael Goldstein, William Harris, Ian Edward David Smith, Teresa Rosanne Welch
Life of this patent
Estimating the term…
Abstract
Alkylamino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives are provided which are useful as inhibitors of p38, along with a process for their manufacture and pharmaceutical preparations containing them.
Claims22
A compound represented by formula I:
- wherein
- the subscript n is an integer of from 0 to 3;
- R1 is a member selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl and aralkyl;
- each R2 is independently selected from the group consisting of alkyl, halo, heteroalkyl and vinyl;
- and
- R3 is a member selected from the group consisting of heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylcarbonyl, heterosubstituted cycloalkyl, heterosubstituted cycloalkylalkyl, heterosubstituted cycloalkylalkenyl, heterosubstituted cycloalkylalkynyl, heteroalkylsubstituted cycloalkyl, heterocyclyl, heterocyclylalkyl, arylheteroalkyl, heteroarylheteroalkyl, -(alkylene)-C(O)R31 and -(heteroalkylene)-C(O)R31;
- wherein
- R31 is a member selected from the group consisting of alkyl, haloalkyl, hydroxy, alkoxy, amino, monsubstituted amino, disubstituted amino, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
- or its pharmaceutically acceptable salts.
6 more elements
A composition comprising a pharmaceutically acceptable excipient and a compound represented by formula (I):
- wherein
- the subscript n is an integer of from 0 to 3;
- R1 is a member selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl and aralkyl;
- each R2 is independently selected from the group consisting of alkyl, halo, heteroalkyl and vinyl;
- and
- R3 is a member selected from the group consisting of heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkylcarbonyl, heterosubstituted cycloalkyl, heterosubstituted cycloalkylalkyl, heterosubstituted cycloalkylalkenyl, heterosubstituted cycloalkylalkynyl, heterosubstituted cycloalkyl, heterocyclyl, heterocyclylalkyl, arylheteroalkyl, heteroarylheteroalkyl, -(alkylene)-C(O)R31 and -(heteroalkylene)-C(O)R31;
- wherein
- R31 is a member selected from the group consisting of alkyl, haloalkyl, hydroxy, alkoxy, amino, monsubstituted amino, disubstituted amino, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
- or its pharmaceutically acceptable salts.
6 more elements
A compound represented by formula I:
- wherein
- the subscript n is an integer of from 0 to 3;
- R1 is a member selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkylcarbonyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl and aralkyl;
- each R2 is independently selected from the group consisting of alkyl, halo, heteroalkyl and vinyl;
- and
- R3 is a member selected from the group consisting of heteroalkylcarbonyl, heterosubstituted cycloalkylalkyl, heterosubstituted cycloalkylalkenyl, heterosubstituted cycloalkylalkynyl, heteroalkylsubstituted cycloalkyl, arylheteroalkyl, heteroarylheteroalkyl, -(alkylene)-C(O)R31 and -(heteroalkylene)-C(O)R31;
- wherein
- R31 is a member selected from the group consisting of alkyl, haloalkyl, hydroxy, alkoxy, amino, monsubstituted amino, disubstituted amino, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, and heteroaralkyl;
- or its pharmaceutically acceptable salts.
6 more elements
Dependencies are inferred from the claim text.